* SCYNEXIS Inc reported a quarterly adjusted loss of 39 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of five analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -22 cents to -17 cents per share.
* Revenue rose 280.4% to $5.80 million from a year ago; analysts expected $1.37 million.
* SCYNEXIS Inc's reported EPS for the quarter was a loss of 39 cents.
* The company reported a quarterly loss of $19.59 million.
* SCYNEXIS Inc shares had fallen by 36.1% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for SCYNEXIS Inc is $7.75 This summary was machine generated from LSEG data March 29 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.20 -0.39 Missed
Sep. 30 2023 -0.15 -0.04 Beat
Jun. 30 2023 1.55 2.46 Beat
Mar. 31 2023 -0.28 -0.71 Missed
Comments